DSGN
Design Therapeutics, Inc.
Biotechnology · Healthcare · United States
10.68
close · 2026-10-30
value
79
cheaper than peers79
quality
83
stronger fundamentals83
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 1 year ago | -8.2% | 76 |
| earnings yield, 3 years ago | -10.7% | 75 |
| earnings yield, 2 years ago | -11.1% | 72 |
| cash flow yield, 1 year ago | -6.5% | 69 |
| cash flow yield, latest year | -8.2% | 67 |
| earnings yield, latest year | -11.4% | 67 |
| cash flow yield, 2 years ago | -8.8% | 61 |
| cash flow yield, 3 years ago | -7.8% | 61 |
| price to book | 3.31× | 41 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -34.1% | 82 |
| debt to equity | 1.3% | 68 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $668M |
| free cash flow | -$32.4M |
| employees | 55 |
| first trade | 2021-03-29 |
| next earnings | 2026-08-03 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.22 | -0.88 | -1.19 | -1.14 |
| free cash flow | -$54.6M | -$43.4M | -$58.8M | -$52.2M |
| net income | -$69.8M | -$49.6M | -$66.9M | -$63.3M |
| revenue | $0 | $0 | $0 | $0 |